Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-29
2009-08-25
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C514S340000, C514S383000, C544S366000, C546S210000, C546S272400, C548S262200, C548S266400, C548S267200
Reexamination Certificate
active
07579352
ABSTRACT:
The present invention is concerned with compounds of formulathe N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents O, S or NR3; R1represents hydrogen, hydroxy, C1-6alkyl or aryl; R2represents hydrogen; optionally substituted C1-12alkyl; C3-7cycloalkyl; C2-8alkenyl; aryl; Het1; R3represents hydrogen, optionally substituted C1-6alkyl, aryl, Het1; R4represents hydrogen; hydroxy; mercapto; C1-6alkyloxy; C1-6alkylthio; aryloxy; arylthio; Het1-oxy; Het1-thio; optionally substituted C1-12alkyl; optionally substituted C2-8alkenyl; optionally substituted C2-8alkynyl; optionally substituted C3-7cycloalkyl; optionally substituted C5-7cycloalkenyl; aryl; Het1; or -Alk-NR3R5(i) or —NR3R5(ii) wherein Alk represents C1-6alkanediyl; and R5represents hydrogen, C1-6alkyl, aryl, Het1, (aryl or Het1)C1-6alkyl, (aryl or Het1)carbonyl or (aryl or Het1)C1-6alkyloxycarbonyl; aryl represents optionally substituted indanyl, indenyl, naphtyl, 5,6,7,8-tetrahydro-2-naphtalenyl or phenyl; Het is triazolyl; and Het1represents an optionally substituted monocyclic or bicyclic heterocycle; having retinoic mimetic activity; their preparation, compositions containing them and their use as a medicine.
REFERENCES:
patent: 4350706 (1982-09-01), Brouwer et al.
patent: 4788206 (1988-11-01), Guthrie et al.
patent: 4880457 (1989-11-01), Parry et al.
patent: 6319939 (2001-11-01), Mabire et al.
patent: 6667278 (2003-12-01), Back et al.
patent: 6936626 (2005-08-01), Mabire et al.
patent: 7179825 (2007-02-01), Mabire et al.
patent: 7241758 (2007-07-01), Hao et al.
patent: 7338962 (2008-03-01), Dolle et al.
patent: 0260744 (1988-03-01), None
patent: 0371559 (1990-06-01), None
patent: 0371564 (1990-06-01), None
patent: 52-83565 (1977-07-01), None
patent: WO 96/39382 (1996-12-01), None
patent: WO 97/16443 (1997-05-01), None
patent: WO 97/49704 (1997-12-01), None
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Oct. 15, 1999, Science, vol. 286, p. 531.
Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, 1998, Cancer and Metastasis, vol. 17, p. 91.
Carmellino, M. et al., “Studies on the Insecticidal Activities of Some NewN-Benzoyl-N′-Arylureas.”,Pesticide Science, 1995, pp. 227-236, vol. 45, No. 3, Great Britain.
Cross, L. et al., “Rules For The Nomenclature of Organic Chemistry, Section E: Stereochemistry.”,Pure&Applied Chemistry, 1976, pp. 13-30, vol. 45., Pergamon Press, Great Britain.
Bouillon, R., et al., “Structure-Function Relationships in the Vitamin D Endocrine System*.”,Endocrine Reviews, 1995, pp. 200-257, vol. 16, No. 2, The Endocrine Society, USA.
Adelinet Christophe Denis
Csoka Imré Christian
Mabire Dominique
Venet Marc Gaston
Bianchi Kristin
Janssen Pharmaceutica N.V.
Saeed Kamal A
LandOfFree
Retinoic acid mimetic anilides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retinoic acid mimetic anilides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retinoic acid mimetic anilides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4097008